I second this. I don't think he or she is being a contrarian for the sake of riling people up. The queries Mason have posted appear to be legitimate and can addressed or rebutted accordingly. There is still a significant amount of uncertainty and risk in Imugene (as with any biotech company specialising in immunotherapy and/or oncolytic product development) despite my belief in what the company is doing and holding shares in the company.
If anything, Mason's queries have prompted me to read the research papers and results thus far more carefully and in detail. For me, a little doubt goes a long way and I welcome more questions by posters.
Why IMU is a multi multi bagger, page-1894
-
- There are more pages in this discussion • 23,739 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add IMU (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
5.3¢ |
Change
-0.001(1.85%) |
Mkt cap ! $389.5M | |||
| Open | High | Low | Value | Volume |
| 5.5¢ | 5.6¢ | 5.3¢ | $615.0K | 11.39M |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 25 | 2977440 | 5.3¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 5.4¢ | 283236 | 4 |
View Market Depth
| Last trade - 16.10pm 30/07/2024 (20 minute delay) ? |
| IMU (ASX) Chart |